Is Neuroone Medical Stock a Good Investment?
Neuroone Medical Investment Advice | NMTC |
- Examine Neuroone Medical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neuroone Medical's leadership team and their track record. Good management can help Neuroone Medical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Neuroone Medical's business and its evolving consumer preferences.
- Compare Neuroone Medical's performance and market position to its competitors. Analyze how Neuroone Medical is positioned in terms of product offerings, innovation, and market share.
- Check if Neuroone Medical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neuroone Medical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neuroone Medical Technologies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neuroone Medical Technologies is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neuroone Medical Stock
Researching Neuroone Medical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.48. Neuroone Medical Tec had not issued any dividends in recent years. The entity had 1:3 split on the 1st of April 2021.
To determine if Neuroone Medical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuroone Medical's research are outlined below:
| Neuroone Medical Tec generated a negative expected return over the last 90 days | |
| Neuroone Medical Tec has some characteristics of a very speculative penny stock | |
| Neuroone Medical Tec has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.95 M. Net Loss for the year was (11.86 M) with loss before overhead, payroll, taxes, and interest of (3.05 M). | |
| Neuroone Medical Technologies currently holds about 10.18 M in cash with (12.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Neuroone Medical Tec has a frail financial position based on the latest SEC disclosures |
Neuroone Medical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuroone Medical Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuroone Medical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Neuroone Medical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neuroone Medical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.1 | -0.1102 | -0.0102 | 10 | ||
2022-12-22 | 2022-09-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2023-12-14 | 2023-09-30 | -0.17 | -0.13 | 0.04 | 23 | ||
2022-08-11 | 2022-06-30 | -0.22 | -0.17 | 0.05 | 22 |
Know Neuroone Medical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuroone Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuroone Medical Technologies backward and forwards among themselves. Neuroone Medical's institutional investor refers to the entity that pools money to purchase Neuroone Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aurum Wealth Management Group Llc | 2024-09-30 | 12 K | Tower Research Capital Llc | 2024-06-30 | 11.4 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.3 K | Bank Of America Corp | 2024-06-30 | 216 | Jpmorgan Chase & Co | 2024-06-30 | 57.0 | Centerpoint Advisors, Llc | 2024-06-30 | 0.0 | Mayo Clinic | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 919.5 K | Nantahala Capital Management, Llc | 2024-09-30 | 798.8 K |
Neuroone Medical's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.98 M.Market Cap |
|
Neuroone Medical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (150.49) | (142.97) | |
| Return On Capital Employed | 0.84 | 0.88 | |
| Return On Assets | (20.23) | (21.25) | |
| Return On Equity | 1.00 | 0.84 |
Determining Neuroone Medical's profitability involves analyzing its financial statements and using various financial metrics to determine if Neuroone Medical is a good buy. For example, gross profit margin measures Neuroone Medical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuroone Medical's profitability and make more informed investment decisions.
Please note, the presentation of Neuroone Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuroone Medical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuroone Medical's management manipulating its earnings.
Evaluate Neuroone Medical's management efficiency
Neuroone Medical Tec has return on total asset (ROA) of (1.4333) % which means that it has lost $1.4333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4913) %, meaning that it created substantial loss on money invested by shareholders. Neuroone Medical's management efficiency ratios could be used to measure how well Neuroone Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.88, whereas Return On Tangible Assets are projected to grow to (142.97). At present, Neuroone Medical's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 11.5 M, whereas Non Currrent Assets Other are projected to grow to (670.7 K).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.29) | (2.17) | |
| Tangible Book Value Per Share | (2.38) | (2.26) | |
| Enterprise Value Over EBITDA | (9.44) | (9.91) | |
| Price Book Value Ratio | (5.25) | (5.51) | |
| Enterprise Value Multiple | (9.44) | (9.91) | |
| Price Fair Value | (5.25) | (5.51) | |
| Enterprise Value | 2.8 M | 2.7 M |
Understanding the operational decisions made by Neuroone Medical management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.909 |
Basic technical analysis of Neuroone Stock
As of the 26th of November, Neuroone Medical secures the Risk Adjusted Performance of (0.01), standard deviation of 4.68, and Mean Deviation of 3.64. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuroone Medical Tec, as well as the relationship between them.Neuroone Medical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuroone Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuroone Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuroone Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuroone Medical's Outstanding Corporate Bonds
Neuroone Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuroone Medical Tec uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuroone bonds can be classified according to their maturity, which is the date when Neuroone Medical Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Neuroone Medical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neuroone Medical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.64 | |||
| Coefficient Of Variation | (3,876) | |||
| Standard Deviation | 4.68 | |||
| Variance | 21.94 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 25.16 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 9.3 | |||
| Skewness | 0.7363 | |||
| Kurtosis | 1.02 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 3.64 | |||
| Coefficient Of Variation | (3,876) | |||
| Standard Deviation | 4.68 | |||
| Variance | 21.94 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 25.16 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 9.3 | |||
| Skewness | 0.7363 | |||
| Kurtosis | 1.02 |
Consider Neuroone Medical's intraday indicators
Neuroone Medical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neuroone Medical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 40091.65 | |||
| Daily Balance Of Power | (0.88) | |||
| Rate Of Daily Change | 0.9 | |||
| Day Median Price | 0.64 | |||
| Day Typical Price | 0.63 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.07) |
Neuroone Stock media impact
Far too much social signal, news, headlines, and media speculation about Neuroone Medical that are available to investors today. That information is available publicly through Neuroone media outlets and privately through word of mouth or via Neuroone internal channels. However, regardless of the origin, that massive amount of Neuroone data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuroone Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuroone Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuroone Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuroone Medical alpha.
Neuroone Medical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neuroone Medical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuroone Medical Corporate Management
| Christopher CFA | Chief Officer | Profile | |
| Hijaz Haris | Vice Marketing | Profile | |
| Ronald McClurg | Chief Officer | Profile | |
| Steven Mertens | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neuroone Medical's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.